CureMatch
×
  • Physicians
  • Patients
  • Employers
  • About Us
  • News
    • CureMatch News
    • Validation and Research
    • Events & Conferences
  • Contact
  • Login
Shumei Kato, MD

Shumei Kato, MD

UC San Diego Health

Shumei Kato, MD, is a board-certified medical oncologist who specializes in treating rare cancers and gastrointestinal tumors. He uses numerous forms of therapy such as chemotherapy, biological therapy, immunotherapy and targeted therapy to offer the best possible treatment options for his patients. Dr. Kato has a special interest in targeted molecular therapy and his approach to care emphasizes personalized medicine and experimental therapeutics.

As an assistant professor in the Department of Medicine, Dr. Kato instructs medical students, residents and fellows. His research interests include clinical trials and the design of new, more effective drugs for individualized therapy.

Dr. Kato has coauthored peer-reviewed articles, which have been published in Nature Cell Biology and the Journal of the National Cancer Institute, among others.

Prior to joining UC San Diego Health, Dr. Kato was an assistant professor in the Department of Investigational Cancer Therapeutics at The University of Texas, MD Anderson Cancer Center in Houston.

Dr. Kato completed a fellowship in investigational cancer therapeutics at MD Anderson Cancer Center, a fellowship in hematology-oncology, and a fellowship in pathology at UC San Diego School of Medicine. He completed his residency training at Nippon Medical School in Tokyo, Japan and at Mount Sinai School of Medicine, Mount Sinai Beth Israel, in New York. Dr. Kato earned his medical degree from Nippon Medical School. He is board-certified in internal medicine and medical oncology.

He is a member of the American Society of Clinical Oncology and the American Association for Cancer Research.

logo

+1 (858) 284-0488

FAX: +1 (858) 430-5813

Quick Links

  • Physicians
  • About CureMatch
  • News and Latest Posts
    • CureMatch News
    • Validation and Case Studies
    • Events and Conferences
  • Contact Us
  • FAQ

Latest News and Results

  • CureMatch Granted CPT® Code by American Medical Association for its Algorithmic Cancer Therapy Ranking Service Jan 4

    Oncologists will be able to submit claims to payers using a Category III CPT code,...

  • CureMatch CEO Navid Alipour named a Top 50 Honoree Leader of Influence in Life Science by San Diego Business Journal Jul 26

    Congratulations to CureMatch CEO Navid Alipour for being named a Top Leader of Influence in...

  • CureMatch Announces the Addition of John S. Link, Jordan Shlain and Greg Simon to Advisory Board Jul 21

    Dr. Link, Dr. Shlain and Mr. Simon all bring deep entrepreneurial experience in the medical...

© 2021 CureMatch, Inc. CureMatch is a registered trademark.
Terms of Use | Privacy Policy | HIPAA Notice

We’d like to send you a CureMatch Sample Analysis

 

Sample Analysis Download Form

  • This field is for validation purposes and should be left unchanged.

 

We value and respect your privacy and will not publish, share, or sell your contact information.

View Privacy Policy

Some pages of this website are intended for healthcare professionals

This webpage is strictly reserved for healthcare professionals. Please confirm that you are a healthcare professional.

Otherwise, you will be redirected to the institutional part of this website.

Thank you for your understanding.

I am a healthcare professionalI am not a healthcare professional

Get ready to utilize the latest genomics data in your practice

Rank the most promising systemic therapies for your patients

Do you need to filter out those therapies with poor outcomes

Sort through 4.5 million expertly curated combinations of drugs

Compute your own drug choices alongside CureMatch data